Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Outpatient Versus Inpatient Administration of Ciltacabtagene Autoleucel in Multiple Myeloma: A Systematic Review of Clinical, Economic, and Humanistic Outcomes
- DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma
- METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation
- Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis
- Ketogenic diet with chemo shows survival trend in pancreatic cancer
- Inovio, Akeso partner on Phase 2 trial of new immunotherapy for glioblastoma
- Immune duo safely targets hard-to-treat gynecological cancers
- Toward a cure for multiple myeloma within a decade
- FDA approves Tecvayli, Darzalex Faspro in combo for hard-to-treat myeloma
- Small molecule screening identifies cytotoxic endoplasmic reticulum-associated degradation inhibitors in multiple myeloma